As it goes with personal investment, your docility is just a confirmation bias. I acknowledge that personal interests should dictate a positive results for all stakeholders, but that doesn’t absolve management of spending oversight at a time when TDG financing is unclear when the transaction was supposed to be completed. Using cheap excuses about management shares or auditor controls is putting blind faith in a place where it is your right and obligation as a shareholder to understand the behaviour of management. It is abnormal that management don’t communicate to a network of individuals whose voice they monitor frequently especially when doubts about issues unrelated to Chatree reopening are raised. Silence is comfortably deafening for many of you and that is abnormal as a responsible investor. Your instinct should be to question, not doubt, but to be curious about how efficient they are at delivering shareholder value. If the stock went to 50c which is plausible on a failed TDG financing, all of you would hit the roof. Emotional bunch hinging on being right. Maybe you will be, but the length of your holding or size of position is not an excuse for ignorance.
- Forums
- ASX - By Stock
- Local News
As it goes with personal investment, your docility is just a...
Featured News
Add KCN (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.27 |
Change
0.010(0.79%) |
Mkt cap ! $327.3M |
Open | High | Low | Value | Volume |
$1.25 | $1.29 | $1.24 | $2.647M | 2.095M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 88319 | $1.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.28 | 7644 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 88319 | 1.250 |
3 | 40096 | 1.245 |
3 | 10382 | 1.240 |
1 | 339 | 1.235 |
3 | 45000 | 1.230 |
Price($) | Vol. | No. |
---|---|---|
1.280 | 7644 | 1 |
1.285 | 7644 | 1 |
1.290 | 7644 | 1 |
1.330 | 20000 | 1 |
1.340 | 2847 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
KCN (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online